We are live on ! Find out more
NEOS

Neos Therapeutics, Inc
NEOS

Delisted

NEOS was delisted on the 19th of March, 2021.

49 hedge funds and large institutions have $65M invested in Neos Therapeutics, Inc in 2017 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 29 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

263% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 8

114% more capital invested

Capital invested by funds: $30.4M → $65M (+$34.6M)

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

6% less funds holding

Funds holding: 5249 (-3)

Holders
49
Holders Change
-3
Holders Change %
-5.77%
% of All Funds
1.22%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
29
Reduced
8
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BAMCO Inc
51
BAMCO Inc
New York
-$412K -70,500 Closed
Susquehanna International Group
52
Susquehanna International Group
Pennsylvania
-$145K -24,821 Closed
CS
53
Credit Suisse
Switzerland
-$91K -15,544 Closed
PA
54
Perceptive Advisors
New York
-$6K -1,056 Closed

NEOS Hedge Fund Activity: Q1 2017 in Review

49 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q1 2017, worth a combined $65M — up 114% from $30.4M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new NEOS positions and 5 closed out — a net gain of 1 holder — while 29 added to existing stakes and 8 trimmed.

The largest buyer was Deerfield Management, adding an estimated $11.6M. The largest seller was Northern Trust, cutting an estimated $1.95M.

  • 49 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q1 2017, down from 52 in Q4 2016.
  • Funds reported $65M of Neos Therapeutics, Inc stock for Q1 2017, up 114% quarter-over-quarter.
  • 6 funds opened new Neos Therapeutics, Inc positions in Q1 2017 and 5 closed out, a net change of +1 holder.
  • The largest Neos Therapeutics, Inc buyer in Q1 2017 was Deerfield Management, an estimated $11.6M added.
  • The largest Neos Therapeutics, Inc seller in Q1 2017 was Northern Trust, an estimated $1.95M sold.

Based on aggregated 13F filings for Q1 2017.